No association between fear of hypoglycemia and blood glucose variability in type 1 diabetes: The cross-sectional VARDIA study by P.Jean Saulnier et al.
No association between fear of hypoglycemia and blood
glucose variability in type 1 diabetes: The cross-sectional
VARDIA study
Submitted by Stéphanie Pinot on Tue, 06/25/2019 - 15:51
Titre No association between fear of hypoglycemia and blood glucose variability in type 1diabetes: The cross-sectional VARDIA study
Type de
publication Article de revue
Auteur
Saulnier, Pierre Jean [1], Briet, Claire [2], Gand, Elise [3], Chaillous, Lucy [4], Dubois,
Séverine [5], Bonnet, Fabrice [6], Leguerrier, Anne Marie [7], Fradet, Gérard [8],
Delcourt Crespin, Ingrid [9], Kerlan, Véronique [10], Gouet, Didier [11], Perlemoine,
Caroline [12], Ducluzeau, Pierre Henri [13], Pichelin, Matthieu [14], Wargny, Matthieu
[15], Gonder-Frederick, Linda [16], Ragot, Stéphanie [17], Hadjadj, Samy [18], Cariou,
Bertrand [19]
Organisme VARDIA study group [20]
Editeur Elsevier








revue Journal of Diabetes and its Complications
ISSN 1873-460X
Mots-clés Epidemiology [21], Hypoglycemia [22], Insulin therapy [23], Psychological aspects[24], Self-management [25]
Résumé en
anglais
AIMS: In type 1 diabetes (T1D), treatment efficacy is limited by the unpredictability of
blood glucose results and glycemic variability (GV). Fear of Hypoglycemia (FOH)
remains a major brake for insulin treatment optimization. We aimed to assess the
association of GV with FOH in participants with T1D in an observational cross-
sectional study performed in 9 French Diabetes Centres (NCT02790060).
METHODS: Participants were T1D for ≥5 years, aged 18-75 years, on stable insulin
therapy for ≥3 months. The coefficient of variation (CV) of blood glucose and mean
amplitude of glycemic excursions (MAGE) were used to assess GV from 7-point self-
monitoring of blood glucose (SMBG). FOH was assessed using the validated French
version of the Hypoglycemia Fear Survey-II (HFS-II) questionnaire.
RESULTS: Among a total of 570 recruited participants, 298 were suitable for analysis:
46% women, 58% on continuous subcutaneous insulin infusion [CSII], mean age
49 ± 16 years, HbA1c 7.5 ± 0.9%, HFS-II score 67 ± 18 and 12% with recent history of
severe hypoglycemia during the previous 6 months, mean CV 39.8 ± 9.7% and MAGE
119 ± 42 mg/dL. CV and MAGE did not significantly correlate with HFS-II score
(R = -0.05;P = 0.457 and R = 0.08;P = 0.170). Participants with severe hypoglycemia in
the previous 6 months had higher HFS scores. Participants with higher HFS scores
presented more hypoglycemias during follow-up.
CONCLUSIONS: FOH as determined using the HFS-II questionnaire was not
associated with 7-point SMBG variability in participants with T1D, but was associated
with a positive history of severe hypoglycemia. Higher FOH was associated with
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